ARCADIA: Phase II proof of concept study of Abatacept (Orencia) in individuals who aRe Considered At risk of Developing Inflammatory Arthritis

Registry ID

EUCTR2015-005285-38

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE2

Sponsor

The University of Leeds

Start date

2020-01-14

Last update

2026-08-16

Conditions

• Inflammatory arthritis

Summary

To obtain preliminary evidence of the clinical efficacy of abatacept in reducing the incidence of inflammatory arthritis in individuals who are at-risk.

Locations

• , , UK

View on source registry